The patient was administered an oral chemotherapy regimen consisting of dabrafenib and trametinib (inhibitors of the associated enzyme B-Raf and the mitogen-activated protein kinase [MEK] pathway which plays a role in the regulation of cell growth), temozolomide (alkylating agent used as a second-line treatment for astrocytoma), and palliative radiation. Here, BRAF is linked to astrocytoma (excluding glioblastoma).